CHL Ltd owns and operates The Suryaa, a luxury hotel in New Delhi, and holds a majority stake in a Hilton-branded hotel in Dushanbe, Tajikistan. The company generates revenue through room rentals, food and beverage services, and wellness facilities.
While the company operates a well-known luxury asset in a prime Delhi location, the financial metrics contradict the existence of a moat. Average ROCE of 0.7% and persistent net losses indicate a lack of competitive advantage and an inability to generate returns above the cost of capital.
Capital allocation has been poor, characterized by heavy investment in a Tajikistan subsidiary that has faced significant litigation and debt defaults. The company has failed to generate meaningful returns on reinvested capital, resulting in negative ROE and stagnant value creation for shareholders.
The Tajikistan subsidiary's legal quagmire finally swallowed the parent company's balance sheet. After the Supreme Court ruled against the company regarding the USD 34 million EXIM Bank guarantee, the thin interest coverage evaporated, forcing a fire sale of the Delhi asset or a dilutive restructuring. The business proved to be a 'value trap' where prime real estate was held hostage by incompetent capital allocation and a management team that prioritized foreign vanity projects over domestic profitability, leaving shareholders with a hollowed-out shell.
RichFakir rates CHL Ltd's business quality as poor — 18/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, CHL Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on CHL Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of CHL Ltd's fair value is about ₹11 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →